ResMed Valuation
Is RMEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RMEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RMEA (€22.6) is trading below our estimate of fair value (€34.52)
Significantly Below Fair Value: RMEA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RMEA?
Key metric: As RMEA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is RMEA's PE Ratio? | |
|---|---|
| PE Ratio | 32.1x |
| Earnings | US$1.11b |
| Market Cap | US$35.45b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.5x |
| Enterprise Value/EBITDA | 22x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does RMEA's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20.2x | ||
SHL Siemens Healthineers | 28.2x | 14.2% | €54.8b |
AFX Carl Zeiss Meditec | 24.1x | 16.3% | €4.9b |
EUZ Eckert & Ziegler | 21.5x | 5.9% | €770.9m |
DRW3 Drägerwerk KGaA | 7.1x | 2.0% | €789.3m |
RMEA ResMed | 32.1x | 11.1% | €35.4b |
Price-To-Earnings vs Peers: RMEA is expensive based on its Price-To-Earnings Ratio (32.1x) compared to the peer average (20.2x).
Price to Earnings Ratio vs Industry
How does RMEA's PE Ratio compare vs other companies in the European Medical Equipment Industry?
| 3 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 3 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: RMEA is expensive based on its Price-To-Earnings Ratio (32.1x) compared to the European Medical Equipment industry average (29.1x).
Price to Earnings Ratio vs Fair Ratio
What is RMEA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32.1x |
| Fair PE Ratio | 30.3x |
Price-To-Earnings vs Fair Ratio: RMEA is expensive based on its Price-To-Earnings Ratio (32.1x) compared to the estimated Fair Price-To-Earnings Ratio (30.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.18
7D
-2.7%
1Y
6.1%
Shandong Weigao Group Medical Polymer
HK$20.7b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.54
7D
-1.8%
1Y
-37.1%
LNA Santé
€242.3m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.8%
1Y
15.7%